SUMOylation of DNMT1 regulates response to catalytic inhibition of DNMT1 in cancer (#157)
Brian Liddicoat
1
,
Wendy Jia
1
,
Naiara GarciaBediaga
1
,
Laura Scolamiero
1
,
Andrew Das
1
,
Christa van der Maarel
1
,
Laure Talarmain
1
,
Cassie Litchfield
1
,
Enid Lam
1
,
Ching-Seng Ang
2
,
Tao Wang
3
,
Francesca Zappacosta
3
,
Roland Annan
3
,
Rab Prinjha
4
,
Melissa Pappalardi
4
,
Michael McCabe
4
,
Mark Dawson
1
- Peter MacCallum Cancer Centre, Melbourne, VICTORIA, Australia
- Proteomic Mass Spectrometry, Bio21, Parkville, Victoria, Australia
- Discovery Analytical Sciences, GlaxoSmithKline, Collegeville, Pennsylvania, USA
- Cancer Epigenetics Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA
Publish consent withheld
- Pappalardi, M.B., Keenan, K., Cockerill, M. et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer 2, 1002–1017 (2021). https://doi.org/10.1038/s43018-021-00249-x